🚀 VC round data is live in beta, check it out!
RenovoRx Valuation Multiples
Discover revenue and EBITDA valuation multiples for RenovoRx and similar public comparables like Passage Bio, Myomo, Karolinska Development, Werewolf Therapeutics and more.
RenovoRx Overview
About RenovoRx
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx’s patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy.
Founded
2012
HQ
Employees
10
Website
Financials (LTM)
EV
$19M
RenovoRx Financials
RenovoRx reported last 12-month revenue of $2M.
In the same LTM period, RenovoRx generated $1M in gross profit and had net loss of ($11M).
Revenue (LTM)
RenovoRx P&L
In the most recent fiscal year, RenovoRx reported revenue of $43K and EBITDA of ($11M).
RenovoRx expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2M | XXX | $43K | XXX | XXX | XXX |
| Gross Profit | $1M | XXX | $43K | XXX | XXX | XXX |
| Gross Margin | 73% | XXX | 100% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($11M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (25512%) | XXX | XXX | XXX |
| EBIT Margin | (617%) | XXX | (25512%) | XXX | XXX | XXX |
| Net Profit | ($11M) | XXX | ($9M) | XXX | XXX | XXX |
| Net Margin | (573%) | XXX | (20498%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
RenovoRx Stock Performance
RenovoRx has current market cap of $29M, and enterprise value of $19M.
Market Cap Evolution
RenovoRx's stock price is $0.79.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $19M | $29M | 0.0% | XXX | XXX | XXX | $-0.24 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialRenovoRx Valuation Multiples
RenovoRx trades at 9.9x EV/Revenue multiple, and (1.7x) EV/EBITDA.
EV / Revenue (LTM)
RenovoRx Financial Valuation Multiples
As of March 21, 2026, RenovoRx has market cap of $29M and EV of $19M.
Equity research analysts estimate RenovoRx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
RenovoRx has a P/E ratio of (2.6x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $29M | XXX | $29M | XXX | XXX | XXX |
| EV (current) | $19M | XXX | $19M | XXX | XXX | XXX |
| EV/Revenue | 9.9x | XXX | 445.4x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (1.7x) | XXX | XXX | XXX |
| EV/EBIT | (1.6x) | XXX | (1.7x) | XXX | XXX | XXX |
| EV/Gross Profit | 13.7x | XXX | 445.4x | XXX | XXX | XXX |
| P/E | (2.6x) | XXX | (3.3x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (2.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified RenovoRx Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
RenovoRx Margins & Growth Rates
RenovoRx's revenue in the last 12 month grew by 256%.
RenovoRx's revenue per employee in the last FY averaged $0.2M.
RenovoRx Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 256% | XXX | 2934% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (25512%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (4%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 347% | XXX | 11600% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 340% | XXX | 14012% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 25612% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
RenovoRx Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Passage Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| Karolinska Development | XXX | XXX | XXX | XXX | XXX | XXX |
| Werewolf Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| NeuroSense Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
RenovoRx M&A Activity
RenovoRx acquired XXX companies to date.
Last acquisition by RenovoRx was on XXXXXXXX, XXXXX. RenovoRx acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by RenovoRx
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialRenovoRx Investment Activity
RenovoRx invested in XXX companies to date.
RenovoRx made its latest investment on XXXXXXXX, XXXXX. RenovoRx invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by RenovoRx
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout RenovoRx
| When was RenovoRx founded? | RenovoRx was founded in 2012. |
| Where is RenovoRx headquartered? | RenovoRx is headquartered in United States. |
| How many employees does RenovoRx have? | As of today, RenovoRx has over 10 employees. |
| Who is the CEO of RenovoRx? | RenovoRx's CEO is Shaun R. Bagai. |
| Is RenovoRx publicly listed? | Yes, RenovoRx is a public company listed on Nasdaq. |
| What is the stock symbol of RenovoRx? | RenovoRx trades under RNXT ticker. |
| When did RenovoRx go public? | RenovoRx went public in 2021. |
| Who are competitors of RenovoRx? | RenovoRx main competitors are Passage Bio, Myomo, Karolinska Development, Werewolf Therapeutics. |
| What is the current market cap of RenovoRx? | RenovoRx's current market cap is $29M. |
| What is the current revenue of RenovoRx? | RenovoRx's last 12 months revenue is $2M. |
| What is the current revenue growth of RenovoRx? | RenovoRx revenue growth (NTM/LTM) is 256%. |
| What is the current EV/Revenue multiple of RenovoRx? | Current revenue multiple of RenovoRx is 9.9x. |
| Is RenovoRx profitable? | No, RenovoRx is not profitable. |
| What is the current net income of RenovoRx? | RenovoRx's last 12 months net income is ($11M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.